We are live on ! Find out more
Carlyle Group

Carlyle Group Portfolio holdings

AUM $10B Turnover 30.43%
1-Year Est. Return 10.61%
This Fund
S&P 500
This Quarter Est. Return
-4.39%
1 Year Est. Return
-10.61%
3 Year Est. Return
-7.98%
5 Year Est. Return
-20.78%
10 Year Est. Return
-1.56%
AUM
$10B
AUM Growth
-$618M
Cap. Flow
-$14.8M
Cap. Flow %
-0.15%
Top 10 Hldgs %
99.94%
Holding
23
New
3
Increased
2
Reduced
2
Closed
4
Avg Time Held
1.9 years
Top 10 Avg Time Held
1.3 years
Top 20 Avg Time Held
1.8 years

Top Sells

Rank Stock Value
1
QTTB icon
Q32 Bio
QTTB
+$8.71M
2
CUBE icon
CubeSmart
CUBE
+$8.08M
3
HTFL icon
Heartflow Inc
HTFL
+$497K
4
SYRE icon
Spyre Therapeutics
SYRE
+$485K
5
XCUR icon
Exicure
XCUR
+$240K

Sector Composition

Rank Sector Weight
1 Healthcare 74.22%
2 Industrials 25.31%
3 Real Estate 0.2%
4 Technology 0.18%
5 Communication Services 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
MDLN icon
1
Medline Inc
MDLN
$30.9B
$7.38B 73.78%
187,083,713
– –
2025 Q4
2 quarters
SARO icon
2
StandardAero Inc
SARO
$7.07B
$2.53B 25.3%
84,587,035
– –
2024 Q4
6 quarters
PHAT icon
3
Phathom Pharmaceuticals
PHAT
$567M
$37.9M 0.38%
3,496,808
– –
2023 Q1
13 quarters
INVH icon
4
Invitation Homes
INVH
$15.8B
$20M 0.2%
662,900
-1,200
-0.2% -$33.9K
2023 Q1
13 quarters
PONY icon
5
Pony AI Inc
PONY
$2.18B
$16.4M 0.16%
2,362,447
– –
2024 Q4
6 quarters
GETY icon
6
DELISTED
GETTY IMAGES HLDGS INC A
GETY
$5.36M 0.05%
6,234,252
– –
2022 Q4
14 quarters
SPRB icon
7
Spruce Biosciences
SPRB
$116M
$2.09M 0.02%
38,620
– –
2025 Q3
3 quarters
SPWR icon
8
SunPower Inc
SPWR
$75.3M
$1.61M 0.02%
2,343,750
+1,910,592
+441% +$1.87M
2023 Q3
11 quarters
ACET icon
9
Adicet Bio
ACET
$42.4M
$1.59M 0.02%
184,295
– –
2023 Q1
13 quarters
FWRD icon
10
Forward Air
FWRD
$518M
$1.45M 0.01%
107,214
– –
2024 Q3
7 quarters
OKUR icon
11
OnKure Therapeutics
OKUR
$91.1M
$1.23M 0.01%
269,895
– –
2023 Q1
13 quarters
DNUT icon
12
Krispy Kreme
DNUT
$512M
$1.2M 0.01%
340,748
– –
2024 Q1
9 quarters
QTTB icon
13
Q32 Bio
QTTB
$232M
$769K 0.01%
60,363
-1,042,378
-95% -$8.71M
2024 Q1
9 quarters
REPX icon
14
Riley Exploration Permian
REPX
$1.09B
$530K 0.01%
+16,092
New +$574K
2026 Q2
0 quarters
NBIS icon
15
Nebius Group N.V.
NBIS
$46.3B
$510K 0.01%
+1,846
New +$366K
2026 Q2
0 quarters
HOOD icon
16
Robinhood
HOOD
$86.8B
$475K ﹤0.01%
4,733
+1,357
+40% +$114K
2025 Q4
2 quarters
JSPR icon
17
Jasper Therapeutics
JSPR
$15.9M
$449K ﹤0.01%
1,066,189
– –
2023 Q1
13 quarters
NABL icon
18
N-able
NABL
$860M
$344K ﹤0.01%
93,732
– –
2024 Q1
9 quarters
METC icon
19
Ramaco Resources Class A
METC
$487M
$288K ﹤0.01%
+21,743
New +$317K
2026 Q2
0 quarters
CUBE icon
20
CubeSmart
CUBE
$8.69B
– –
-220,500
Closed -$8.08M –
SYRE icon
21
Spyre Therapeutics
SYRE
$7.92B
– –
-9,620
Closed -$485K –
XCUR icon
22
Exicure
XCUR
$6.74M
– –
-56,328
Closed -$240K –
HTFL icon
23
Heartflow Inc
HTFL
$4.44B
– –
-20,438
Closed -$497K –

Similar funds

Carlyle Group's Q2 2026 Portfolio in Review

As of Q2 2026, Carlyle Group held 23 positions worth $10B, down 5.8% from $10.6B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Carlyle Group's Q2 2026 filing shows 3 new, 2 increased, 2 reduced and 4 closed positions. Its largest new stake was Riley Exploration Permian: 16,092 shares worth $530K. The largest sale was Q32 Bio, an estimated $8.71M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 79% a quarter earlier, followed by Industrials and Real Estate.

  • Carlyle Group's largest Q2 2026 buy was Riley Exploration Permian: 16,092 shares worth $530K.
  • Carlyle Group added most to SunPower Inc in Q2 2026, an estimated $1.87M increase.
  • Carlyle Group's biggest Q2 2026 reduction was Q32 Bio, cutting an estimated $8.71M.
  • Carlyle Group fully exited CubeSmart in Q2 2026, selling an estimated $8.08M.
  • Carlyle Group's ten largest holdings make up 100% of its $10B portfolio in Q2 2026.
  • Carlyle Group opened 3 new positions and closed 4 in Q2 2026.
  • Carlyle Group's portfolio value fell 5.8% quarter-over-quarter to $10B.

Based on Carlyle Group's 13F filing for Q2 2026, filed 7 Aug 2026.